NCT05691465 2026-03-18
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04298541 2026-02-27
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Phase 2 Not yet recruiting
NCT04074135 2026-02-24
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03206060 2026-02-17
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07284589 2025-12-16
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT04082520 2025-12-11
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT03602911 2025-03-12
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
West Virginia University
Phase 2 Completed
NCT00001277 2022-06-07
Studies of Elevated Parathyroid Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT03125629 2021-04-09
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
Stanford University
Phase 2 Completed
NCT01967537 2019-11-19
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed